Stein, MD, professor and co-director of the Acute Leukemia Program at City of Hope in Duarte, California, provides deeper insight into the trial design and key findings in an interview with Targeted ...
Newser on MSN12h
Was It Her 1970s Pajamas? Chemist Reflects on Her CancerWhen Alison Spodek was diagnosed with acute myeloid leukemia in 2013, she did what many new cancer patients do: wondered when ...
Identifying the JAK2V617F mutation has improved understanding of what causes overproduction of red blood cells, platelets, ...
CERo’s technology works by grafting onto patients’ own T-cells a receptor that binds to a naturally occurring human antigen ...
– Reported Positive Overall Survival and Overall Response Rate Data from the Ongoing Phase 2 Trial of SLS009 (Tambiciclib) in r/r AML – Full Data and FDA Regulatory Path Feedback Expected in 1H 2025 – ...
Aptevo Therapeutics reports strong remission rates in AML patients using mipletamig plus ven/aza, with Cohort 2 enrollment ...
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...
JPMorgan raised the firm’s price target on Syndax (SNDX) to $41 from $39 and keeps an Overweight rating on the shares after having surveyed 23 ...
The journey of fighting Acute Myeloid Leukemia (AML) in India encompasses severe physical and emotional challenges for both ...
CERo Therapeutics (CERO) announces an agreement with the University of California Davis for the manufacturing of CER-1236 to be used in the ...
Jon Batiste shared a positive update on his wife Suleika Jaouad's health following her September 2024 announcement that she'd ...
Treatment with the T-cell immunotherapy Orca-T improved survival free of moderate-to-severe chronic graft-versus-host disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback